NasdaqGS:OMCL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Omnicell's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OMCL has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

6.9%

OMCL

0.4%

US Healthcare Services

1.8%

US Market


1 Year Return

3.3%

OMCL

56.8%

US Healthcare Services

14.2%

US Market

Return vs Industry: OMCL underperformed the US Healthcare Services industry which returned 56.8% over the past year.

Return vs Market: OMCL underperformed the US Market which returned 14.2% over the past year.


Shareholder returns

OMCLIndustryMarket
7 Day6.9%0.4%1.8%
30 Day12.9%-2.9%0.04%
90 Day10.9%11.6%9.8%
1 Year3.3%3.3%57.3%56.8%16.7%14.2%
3 Year55.2%55.2%104.4%103.1%41.6%32.2%
5 Year147.3%147.3%151.9%149.6%90.9%69.5%

Price Volatility Vs. Market

How volatile is Omnicell's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Omnicell undervalued compared to its fair value and its price relative to the market?

0.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OMCL ($76.84) is trading below our estimate of fair value ($77.1)

Significantly Below Fair Value: OMCL is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: OMCL is poor value based on its PE Ratio (66.1x) compared to the US Healthcare Services industry average (54.4x).

PE vs Market: OMCL is poor value based on its PE Ratio (66.1x) compared to the US market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: OMCL is poor value based on its PEG Ratio (1.2x)


Price to Book Ratio

PB vs Industry: OMCL is good value based on its PB Ratio (3.7x) compared to the US Healthcare Services industry average (5.4x).


Next Steps

Future Growth

How is Omnicell forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

54.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OMCL's forecast earnings growth (54.2% per year) is above the savings rate (2.2%).

Earnings vs Market: OMCL's earnings (54.2% per year) are forecast to grow faster than the US market (23.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: OMCL's revenue (10.6% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: OMCL's revenue (10.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OMCL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Omnicell performed over the past 5 years?

27.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OMCL has high quality earnings.

Growing Profit Margin: OMCL's current net profit margins (5.4%) are lower than last year (5.7%).


Past Earnings Growth Analysis

Earnings Trend: OMCL's earnings have grown significantly by 27.5% per year over the past 5 years.

Accelerating Growth: OMCL's earnings growth over the past year (2.8%) is below its 5-year average (27.5% per year).

Earnings vs Industry: OMCL earnings growth over the past year (2.8%) exceeded the Healthcare Services industry -4.8%.


Return on Equity

High ROE: OMCL's Return on Equity (5.5%) is considered low.


Next Steps

Financial Health

How is Omnicell's financial position?


Financial Position Analysis

Short Term Liabilities: OMCL's short term assets ($465.2M) exceed its short term liabilities ($236.6M).

Long Term Liabilities: OMCL's short term assets ($465.2M) exceed its long term liabilities ($98.4M).


Debt to Equity History and Analysis

Debt Level: OMCL is debt free.

Reducing Debt: OMCL had no debt 5 years ago.

Debt Coverage: OMCL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: OMCL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Omnicell current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OMCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OMCL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OMCL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OMCL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OMCL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Randy Lipps (63 yo)

17.92yrs

Tenure

US$7,208,973

Compensation

Mr. Randall A. Lipps, also known as Randy, founded Omnicell, Inc. in September 1992 and has been its Chief Executive Officer and President since October 2002. Mr. Lipps had been Executive Chairman and Exec ...


CEO Compensation Analysis

Compensation vs Market: Randy's total compensation ($USD7.21M) is about average for companies of similar size in the US market ($USD5.71M).

Compensation vs Earnings: Randy's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Randall Lipps
Founder17.92yrsUS$7.21m0.94%
$ 30.8m
Peter Kuipers
Executive VP & CFO5.08yrsUS$2.92m0.13%
$ 4.2m
Daniel Johnston
Executive VP5.58yrsUS$1.67m0.067%
$ 2.2m
Nhat Ngo
Executive VP of Marketingno dataUS$1.76m0.068%
$ 2.2m
Scott Seidelmann
Executive VP & Chief Commercial Officer2.42yrsUS$2.67m0.073%
$ 2.4m
Joseph Spears
Senior VP2.92yrsno data0.037%
$ 1.2m
Giri Chodavarapu
Senior VP & Chief Information Officer1yrno datano data
Susan Moriconi
Senior VP & Chief Human Resources Officer1yrno datano data
Jorge Taborga
Executive Vice President of Engineering & Integration Management Officer13.17yrsno data0.082%
$ 2.7m
Corinne Augustine
Senior VP and Chief Manufacturing & Supply Chain Officer1yrno datano data
Diane Kaye
Senior VP & Chief Product Officer1yrno datano data
Vicki Gigliotti
Chief of Staff3.17yrsno datano data

2.9yrs

Average Tenure

56yo

Average Age

Experienced Management: OMCL's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Randall Lipps
Founder17.92yrsUS$7.21m0.94%
$ 30.8m
James Judson
Lead Independent Directorno dataUS$324.93k0.051%
$ 1.7m
Mark Parrish
Independent Director7.67yrsUS$283.73k0.078%
$ 2.6m
Sara White
Independent Director17.42yrsUS$276.97k0.093%
$ 3.1m
Robin Seim
Director1.5yrsUS$396.59k0.086%
$ 2.8m
Joanne Bauer
Independent Director6.67yrsUS$299.97k0.044%
$ 1.4m
Vance Moore
Independent Director8.33yrsUS$269.98k0.094%
$ 3.1m
Bruce Scott
Independent Director1.33yrsUS$380.82k0.011%
$ 346.0k
Bruce Smith
Independent Director6.33yrsUS$264.94k0.053%
$ 1.7m

7.2yrs

Average Tenure

64yo

Average Age

Experienced Board: OMCL's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.


Top Shareholders

Company Information

Omnicell, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Omnicell, Inc.
  • Ticker: OMCL
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$3.286b
  • Shares outstanding: 42.76m
  • Website: https://www.omnicell.com

Number of Employees


Location

  • Omnicell, Inc.
  • 590 East Middlefield Road
  • Mountain View
  • California
  • 94043
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OMCLNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2001
OC9DB (Deutsche Boerse AG)YesCommon StockDEEURAug 2001

Biography

Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 07:08
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.